ArticleJournal of clinical microbiology2007
Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. Tested by clinical and laboratory standards institute-recommended broth microdilution methods.
Article in Journal of clinical microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 77 citations in OpenAlex.
- Antifungal Activity of the Essential Oil ofEvidence-based complementary and alternative medicine : eCAM · 2020Article
- Twenty Years of the SENTRY Antifungal Surveillance Program: Results forOpen forum infectious diseases · 2019Article
- Resistance rates of non-Infection and drug resistance · 2019Article
- Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.Folia microbiologica · 2017Article
- Clotrimazole Drug Resistance in Candida glabrata Clinical Isolates Correlates with Increased Expression of the Drug:H(+) Antiporters CgAqr1, CgTpo1_1, CgTpo3, and CgQdr2.Frontiers in microbiology · 2016Article
- Molecular identification andCurrent medical mycology · 2015Article
- In Vitro Susceptibilities of Candida albicans Isolates to Antifungal Agents in Tokat, Turkey.Jundishapur journal of microbiology · 2015Article
- Use of anidulafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 4,290 clinical isolates of Candida by using CLSI methods and interpretive criteria.Journal of clinical microbiology · 2014Article
- Article
- Impact of new antifungal breakpoints on antifungal resistance in Candida species.Journal of clinical microbiology · 2014Article
- Use of micafungin as a surrogate marker to predict susceptibility and resistance to caspofungin among 3,764 clinical isolates of Candida by use of CLSI methods and interpretive criteria.Journal of clinical microbiology · 2014Article
- Use of the VITEK 2 system to identify and test the antifungal susceptibility of clinically relevant yeast species.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2013Article
- Antifungal activities of diphenyl diselenide alone and in combination with fluconazole or amphotericin B against Candida glabrata.Mycopathologia · 2013Article
- Michael A. Pfaller, M.D.Journal of clinical microbiology · 2013Article
- Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents.BioMed research international · 2013Review
- Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.The Kaohsiung journal of medical sciences · 2012Article
- In vitro activities of new triazole antifungal agents, posaconazole and voriconazole, against oral Candida isolates from patients suffering from denture stomatitis.Mycopathologia · 2012Article
- Evaluation of antifungal susceptibility testing with microdilution and Etest methods of Candida blood isolates.Mycopathologia · 2011Article
- Antifungal susceptibility of bloodstream Candida isolates in Sfax hospital: Tunisia.Mycopathologia · 2011Article
- Fixed-ratio combination testing of an echinocandin, anidulafungin, and an azole, voriconazole, against 1,467 Candida species isolates.Antimicrobial agents and chemotherapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clinical laboratories frequently face the problem of delayed availability of commercially prepared approved reagents for performing susceptibility testing of new antimicrobials. Although this problem is encountered more often with antibacterial agents, it is also an issue with antifungal agents. A current example is voriconazole, a new triazole antifungal with an expanded spectrum and potency against Candida spp., Aspergillus spp., and other opportunistic fungal pathogens. The present study addresses the use of fluconazole as a surrogate marker to predict the susceptibility of Candida spp. to voriconazole. Reference broth microdilution MIC results for 13,338 strains of Candida spp. isolated from more than 200 medical centers worldwide were used. Voriconazole MICs and interpretive categories (susceptible, < or =1 microg/ml; susceptible dose dependent, 2 microg/ml; resistant, > or =4 microg/ml) were compared with those of fluconazole by regression statistics and error rate bounding analyses. For all 13,338 isolates, the absolute categorical agreement was 91.6% (false susceptible or very major error [VME], 0.0%). Since voriconazole is 16- to 32-fold more potent than fluconazole, the performance of fluconazole as a surrogate marker for voriconazole susceptibility was improved by designating those isolates with fluconazole MICs of < or =32 microg/ml as being susceptible to voriconazole, resulting in a categorical agreement of 97% with 0.1% VME. Clinical laboratories performing antifungal susceptibility testing of fluconazole against Candida spp. can reliably use these results as surrogate markers until commercial FDA-approved voriconazole susceptibility tests become available.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.